Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Support for the Resumption of Training of High-level Athletes Post-epidemic COVID-19 (ASCCOVID19)

22 czerwca 2021 zaktualizowane przez: University Hospital, Bordeaux

As of March 2020, COVID-19 has become a global pandemic, halting athletic competition worldwide.

Reports from China show a high prevalence of cardiac involvement in patients with severe SARS-CoV-2 infection. These cardiac forms were found to be closely associated with adverse outcomes. The use of Magnetic resonance Imaging (MRI) had allowed to show that cardiac dysfunction could be mediated by myocardial inflammation (i.e. myocarditis). The direct implication of the virus was demonstrated with Severe Acute Respiratory Syndrome (SARS)-CoV-2 being detected on myocardial biopsies in a patient with severe heart failure.

The experience with other viruses causing acute myocarditis shows that there is a high rate of undetected injuries. Indeed, although severe heart failure can be present at the acute stage, acute viral myocarditis is most commonly pauci or asymptomatic, but still leaving occult myocardial scars visible on MRI, and exposing to higher risks of ventricular arrhythmia and sudden cardiac death over the long term.

Although athletes are younger and have fewer comorbidities than the general population and therefore are at lower risk for severe disease or death, there is a critical and urgent need to assess the prevalence of occult scars in the population of high-level athletes returning to training after the SARS-CoV-2 pandemia.

Przegląd badań

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

984

Faza

  • Nie dotyczy

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

      • Angoulême, Francja, 16000
        • Training center Soyaux Angoulême XV Rugby
      • Aurillac, Francja, 15000
        • Training Center Stade Aurillacois
      • Bayonne, Francja, 64104
        • Aviron Bayonnais Rugby Pro Training Center
      • Biarritz, Francja, 64200
        • Biarritz Olympique Pays Basque training center
      • Bordeaux, Francja, 33076
        • Bordeaux University Hospital - CRB medical office - Hôpital du Tondu
      • Bordeaux, Francja, 33076
        • Bordeaux University Hospital - Service UDH - Hôpital Pellegrin
      • Brive-la-Gaillarde, Francja, 19100
        • CABCL Rugby Training Center
      • Bègles, Francja, 33130
        • Union Bordeaux-Bègles training center
      • Carcassonne, Francja, 11000
        • US Carcassonne Rugby training center
      • Colomiers, Francja, 31770
        • Union Sportive Colomiers Rugby training center
      • Grenoble, Francja, 38100
        • FC Grenoble Rugby training center
      • La Rochelle, Francja, 17000
        • Stade Rochelais Rugby training center
      • Le Plessis-Robinson, Francja, 92350
        • Racing92 training center
      • Montauban, Francja, 82000
        • AS Montauban Rugby training center
      • Nevers, Francja, 58000
        • US Nevers Rugby training center
      • Paris, Francja, 75016
        • Stade Français training center
      • Pau, Francja, 64000
        • Section Paloise Rugby training center
      • Perpignan, Francja, 66000
        • USAP Training Center
      • Romans-sur-Isère, Francja, 26100
        • Training center Valence Romans Drôme Rugby
      • Saix, Francja, 81710
        • Castres Olympique training center
      • Toulouse, Francja, 31200
        • Stade Toulousain Rugby training center

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat i starsze (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Tak

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  • High level athlete,
  • Of both sexes and age ≥ 18 years,
  • Affiliated to or beneficiary of a social security system,
  • Free, informed, written consent signed by the participant and the investigating physician (no later than the day of inclusion and before any examination required by the research),
  • Effective method of contraception for women with childbearing capacity.

Exclusion Criteria:

  • Minor,
  • History of ventricular arrhythmia, myocarditis, identified coronary artery disease or documented myocardial fibrosis,
  • Pregnant or breastfeeding women,
  • Person unable to give informed consent,
  • Person deprived of liberty by judicial or administrative decision,
  • Adults subject to a legal protection measure (guardianship, curator, safeguard of justice).

Specific exclusion criteria for the MRI component (Contraindications):

  • Subject with an implantable pacemaker or defibrillator, intraocular metallic foreign body, intracranial metallic clip, pre 6000 Starr-Edwards type cardiac valve prosthesis, or biomedical device such as insulin pump or neurostimulator,
  • Hypersensitivity to gadolinium or to one of the excipients of the contrast product used,
  • Claustrophobic subjects or those unable to remain in an immobile lying position for 30 minutes,
  • Renal insufficiency with creatinine clearance of less than 30 ml/min,
  • A patient whose shoulder width does not allow installation in the MRI machine.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Zapobieganie
  • Przydział: Nie dotyczy
  • Model interwencyjny: Zadanie dla jednej grupy
  • Maskowanie: Brak (otwarta etykieta)

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: High-level athletes

High level athletes are rugby players, intervention unit agents of the National Police, sports students.

Definition of a COVID-19 positive subject : Any subject whose serology is positive (IgM and/or IgG) and/or the Reverse Transcription Polymerase Chain Reaction (RT-PCR) result is positive and/or the questionnaire is positive and/or a new electrocardiogram (ECG) abnormality.

The COVID-19 negative subjects do not meet the definition of COVID-19 positive subjects.

An ECG at rest is performed for all participants at Day 0. A centralized reading is performed by one of the 6 expert cardiologists participating in the research.
In case of positive COVID-19 serology and/or positive COVID-19 RT-PCR and/or new ECG abnormality and/or positive questionnaire, a stress test is performed.
In case of positive COVID-19 serology and/or positive COVID-19 RT-PCR and/or new ECG abnormality and/or positive questionnaire, a Cardiac echocardiography is performed.
In case of positive COVID-19 serology and/or positive COVID-19 RT-PCR and/or new ECG abnormality and/or positive questionnaire, a Cardiac rhythm monitoring is performed.
To determine the rhythmic risk of athletes

High resolution MRIs is performed on 200 athletes :

  • 100 athletes without rhythmic abnormalities (50 individuals with positive COVID-19 status and 50 individuals with negative COVID-19 status)
  • 100 athletes with rhythmic abnormalities (50 individuals with positive COVID-19 status and 50 individuals with negative COVID-19 status)

For all athletes included at the D0 inclusion visit, a centralized COVID-19 serology is performed to search for biomarkers associated with the occurrence of myocardial fibrosis: analysis of genetic determinants in relation to cardiac damage.

For athletes who have performed MRI: Search for biomarkers associated with the occurrence of myocardial fibrosis: analyses of low-grade inflammation markers (cytokine assay and fibrosis markers).

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Presence of rhythmic risk markers bye the questionnaire
Ramy czasowe: Day 0
Questionnaire looking for heart palpitations, chest pain/pressure and shortness of breath.
Day 0
Evaluation by resting ECG of rhythmic risk marker : repolarization disorders
Ramy czasowe: Day 0
Presence or absence of repolarization disorders
Day 0
Evaluation by resting ECG of rhythmic risk marker : inverted T waves
Ramy czasowe: Day 0
Presence or absence of inverted T waves
Day 0
Evaluation by resting ECG of rhythmic risk marker : ST segment abnormalities
Ramy czasowe: Day 0
Presence or absence of ST segment abnormalities
Day 0
Evaluation by resting ECG of rhythmic risk marker : QRS fragmentation
Ramy czasowe: Day 0
Presence or absence of QRS fragmentation
Day 0
Evaluation by resting ECG of rhythmic risk marker : ventricular extrasystoles (VES)
Ramy czasowe: Day 0
Presence or absence of VES. Ventricular extrasystoles especially with short coupling (<300ms), falling on the T wave, width > 160ms, complex forms (repetitive, several morphologies, instantaneous cycle >200bpm)
Day 0
Evaluation by resting ECG of rhythmic risk marker : ventricular tachycardia (VT)
Ramy czasowe: Day 0
Presence or absence of VT.
Day 0
Presence of rhythmic risk markers bye the stress test
Ramy czasowe: Day 0
VES, especially with short coupling (<300ms), falling on the T wave, width > 160ms, complex shapes (repetitive, several morphologies, instantaneous cycle >200bpm), ventricular tachycardias (VT). The analysis focus on the exercise period, and the recovery period. Ventricular arrhythmias will be quantified.
Day 0
Presence of rhythmic risk markers bye ECG holter
Ramy czasowe: Day 0
VES, especially with short coupling (<300ms), falling on the T wave, width > 160ms, complex shapes (repetitive, multiple morphologies, instantaneous cycle >200bpm), ventricular tachycardias (VTs). Ventricular arrhythmias are quantified.
Day 0
Presence of rhythmic risk markers bye ECG monitoring during games and trainings
Ramy czasowe: Day 0
In case of moderate arrhythmia on stress test and/or Holter ECG, ECG monitoring during training sessions and matches is carried out with analysis of the tracings collected, in search of more sustained arrhythmia, particularly at the ventricular level.
Day 0
Presence of rhythmic risk markers by pharmacological tests and/or electrophysiological exploration
Ramy czasowe: Day 0
If the risk is perceived as very high, pharmacological tests (Isuprel®) and/or electrophysiological exploration may be performed during hospitalization, in search of dangerous rhythm disorders, particularly at the ventricular level.
Day 0

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Presence of myocardial fibrosis by injected MRI
Ramy czasowe: Month 3
In order to compare the prevalence of myocardial fibrosis between COVID-19 positive and COVID-19 negative individuals in high level athletes with or without rhythmic risk, a high resolution MRI is performed. The examinations is performed on 1.5 or 3T MRI systems equipped with specific antennas for cardiology. The sequence used to detect occult scars is a late enhancement sequence performed at least 15 minutes after injection of gadolinium salts, using a free-breathing 3D method, for a minimum spatial resolution of 2.5x1.25x1.25mm. The images are reviewed by a core lab at the Bordeaux University Hospital. The presence or absence of myocardial fibrosis is evaluated.
Month 3
Presence of transmural localization of myocardial fibrosis by injected MRI
Ramy czasowe: Month 3
In order to compare the prevalence of myocardial fibrosis between COVID-19 positive and COVID-19 negative individuals in high level athletes with or without rhythmic risk, a high resolution MRI is performed. The examinations is performed on 1.5 or 3T MRI systems equipped with specific antennas for cardiology. The sequence used to detect occult scars is a late enhancement sequence performed at least 15 minutes after injection of gadolinium salts, using a free-breathing 3D method, for a minimum spatial resolution of 2.5x1.25x1.25mm. The images are reviewed by a core lab at the Bordeaux University Hospital. The presence or absence of transmural localization is evaluated.
Month 3
Measurement of cardiac scar size by injected MRI
Ramy czasowe: Month 3
In order to compare the prevalence of myocardial fibrosis between COVID-19 positive and COVID-19 negative individuals in high level athletes with or without rhythmic risk, a high resolution MRI is performed. The examinations is performed on 1.5 or 3T MRI systems equipped with specific antennas for cardiology. The sequence used to detect occult scars is a late enhancement sequence performed at least 15 minutes after injection of gadolinium salts, using a free-breathing 3D method, for a minimum spatial resolution of 2.5x1.25x1.25mm. The images are reviewed by a core lab at the Bordeaux University Hospital. The size of scars is measured in milliliters (mL).
Month 3
Search for constitutional genetic biomarkers
Ramy czasowe: Month 5
identification by sequencing of genetic variants that could have an impact on the occurrence of a severe form in individuals infected with SARS-CoV-2.
Month 5
Research of inflammation markers
Ramy czasowe: Month 5
Th1/Th2/activation/inflammation/apoptosis markers are measured in sera by a Luminex test allowing the detection of 10 analytes with a commercial kit according to the manufacturer's instructions
Month 5

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Śledczy

  • Krzesło do nauki: Antoine Bénard, MD, University Hospital, Bordeaux
  • Główny śledczy: Laurent Chevalier, MD, Medical Center of the Bordeaux-Mérignac Sports Clinic

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

18 czerwca 2020

Zakończenie podstawowe (Rzeczywisty)

2 marca 2021

Ukończenie studiów (Rzeczywisty)

2 marca 2021

Daty rejestracji na studia

Pierwszy przesłany

2 czerwca 2021

Pierwszy przesłany, który spełnia kryteria kontroli jakości

22 czerwca 2021

Pierwszy wysłany (Rzeczywisty)

23 czerwca 2021

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

23 czerwca 2021

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

22 czerwca 2021

Ostatnia weryfikacja

1 czerwca 2021

Więcej informacji

Terminy związane z tym badaniem

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Badania kliniczne na COVID-19

3
Subskrybuj